IMUGENE LIMITED — Director's Dealing 2019

Apr 22, 2019

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: Imugene Limited (ASX:IMU) ABN: 99 009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Dr. Lesley Russell
Date of Appointment:	23 April 2019

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number	Class of Securities
Nil	Nil

• See chapter 19 for defined terms.

11/3/2002

Appendix 3X Page 1

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interestNote: Provide details of the circumstances giving rise to therelevant interest.	Number	Class of Securities
Nil	Nil	Nil

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Employment Contract
Nature of interest	25,000,000*unlistedoptionsgrantedfromtheCompany’s Employee share option plan (ESOP)subject to shareholder approval at the Company’snext shareholder meeting.The options will be granted in accordance with theterms of the Company’s ESOP and will include thefollowing terms and conditions:Issue price: Nil;Exercise Price will be:i.5,000,000 at $0.04 per option;ii.10,000,000 at $0.042 per option;iii.10,000,000 at $0.045 per optionExpiry Date: 3 years from the date of receivingshareholder approval.Vesting conditions: Vested over 24 months from thedate of receiving shareholder approval.
Name of registered holder(if issued securities)	N/A
No. and class of securities towhich interest relates	25,000,000* unlisted options

*issuance of these securities is subject to receipt of shareholder approval at the Company’s next shareholder meeting.

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002